article thumbnail

Subcutaneous Medications and Drug Delivery Systems

Roots Analysis

Having reported over 70% increase in revenues over the past 5-6 years, the market for biologically derived products is currently estimated to be worth more than USD 200 billion. Our Social Media Platform Web: [link] LinkedIn: [link] Twitter: [link] The post Subcutaneous Medications and Drug Delivery Systems appeared first on Blog.

article thumbnail

Polymer-based drug delivery system for mRNA wins Excellence Award

Drug Discovery World

A new polymer-based drug delivery system for mRNA and other nucleic acids has won the CPHI Excellence in Pharma Award in the category “Packaging and Drug Delivery”. . The system was developed by Evonik Health Care together with researchers at Stanford University. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gerresheimer develops delivery device for drugs with higher viscosity

BioPharma Reporter

CPhI Worldwide will see Gerresheimer showcase its latest developments in primary packaging, drug delivery systems for newly developed biologics along with medical and diagnostic products.

article thumbnail

Meeting global demand for patient independence: SHL Medical expands production in Charleston, US

Pharmaceutical Technology

SHL Medical is a world-leading solutions provider for advanced drug delivery systems with a unified purpose to further enable patient independence. The company’s most prominent products are its autoinjectors, which are seeing growing global demand. Growing demand for patient independence. Choosing Charleston.

article thumbnail

Scilex buys rights to acute migraine treatment Elyxyb in Canada and the US

Pharmaceutical Technology

Elyxyb is a prescription nonsteroidal anti-inflammatory drug (NSAID) used for acute migraine treatment in adult patients with or without aura. It is formulated using a self-micro-emulsifying drug delivery system that improves the drug’s bioavailability and solubility.

article thumbnail

Hydrocortisone by Antares Pharma for Adrenal Insufficiency: Likelihood of Approval

Pharmaceutical Technology

Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is administered by parenteral route.

article thumbnail

Liposomes Development: Service Providers Landscape

Roots Analysis

Presently, outsourcing of liposomes development and manufacturing related services has become a popular practice. Drug developers are actively outsourcing their operations to specialized repurposed-based service providers, which are known to have the required capabilities and expertise.